Metronidazole is administered as a prodrug, meaning it enters pathogen cells in an inert form and must be chemically reduced inside the cell before it can inflict damage. This requirement for intracellular activation is not a design flaw but the secret of the drug’s exquisite selectivity. Anaerobic and microaerophilic organisms, which include the amoeba Entamoeba histolytica, the intestinal flagellate Giardia lamblia, the sexually transmitted parasite Trichomonas vaginalis, and the stomach-dwelling bacterium Helicobacter pylori, rely on low-redox-potential fermentation pathways that oxygen-dependent human cells lack. These pathways unwittingly serve as activation machinery, reducing the nitro group of metronidazole to generate short-lived nitro radical anions. Once formed, these radicals transfer electrons to oxygen or to cellular macromolecules, ultimately producing DNA strand breaks, protein damage, and other lesions that trigger catastrophic cell death. The drug, in effect, hijacks the very biochemistry that lets these pathogens survive without oxygen.

The review delineates four major activation pathways, along with an additional route that appears to operate only in Trichomonas. The classical and best-characterized route runs through pyruvate-ferredoxin oxidoreductase, or PFOR, an enzyme central to anaerobic energy metabolism. PFOR passes electrons to low-molecular-weight electron carriers such as ferredoxin, and metronidazole acts as an electron acceptor downstream of these carriers, receiving the electrons that convert it into its cytotoxic radical form. This arrangement explains why disruptions to PFOR expression or to ferredoxin-mediated electron transport so frequently accompany resistance in Entamoeba, Giardia, and Trichomonas. When the electron pipeline that feeds the drug’s activation is throttled back, less of the prodrug is converted into its lethal form, and the parasite gains a survival advantage.

Beyond the classical pathway, the review highlights a family of enzymes known as oxygen-insensitive nitroreductases, or NTRs, which can activate metronidazole independently of the ferredoxin-linked machinery. These nitroreductases reduce the nitro group through a two-electron mechanism that does not require the extremely low oxygen tensions that inhibit other reductive routes. Their existence demonstrates that pathogen cells possess redundant means of arming the drug, a feature that complicates resistance strategies because a parasite must suppress every activation pathway to fully protect itself. Indeed, the review emphasizes that resistant isolates often show layered changes, combining reduced PFOR activity with altered nitroreductase expression and shifts in overall redox metabolism.

Counterbalancing the activators are enzymes that perform the opposite function. Nitroimidazole reductases, known as NIMs, reduce metronidazole in a manner that avoids the formation of the toxic nitro radical, instead converting the compound into non-cytotoxic derivatives. In Entamoeba, the presence or upregulation of such detoxifying activity can dramatically blunt the drug’s effectiveness, contributing directly to resistance phenotypes. The balance between activation enzymes and detoxification enzymes therefore functions as a molecular seesaw: the tipping point determines whether a given dose of metronidazole sterilizes the infection or merely selects for a hardier parasite population. Understanding the genetic and environmental factors that tilt this balance is now a central goal for researchers seeking reliable biomarkers of treatment failure.

Perhaps the most striking recent advance documented in the review is the identification of an alternative activation route involving the malic enzyme. This metabolic enzyme, long appreciated for its role in decarboxylating malate and shuttling reducing equivalents within parasite cells, appears capable of reducing metronidazole and thereby contributing to its activation. The discovery expands the roster of host enzymes that the drug can co-opt and suggests that resistance mechanisms targeting only the classical PFOR-ferredoxin axis may leave this secondary route intact. It also raises intriguing questions about how metabolic flux within the parasite cell, shaped by nutrient availability and environmental conditions, might modulate drug efficacy from one infection context to another.

Equally consequential is the emerging understanding of how activated metronidazole actually kills the parasite. Rather than a nonspecific barrage of radical damage, cell death in Entamoeba histolytica appears to unfold through an organized program. The review’s authors report that metronidazole-associated oxidative stress induces the activation of apoptosis-inducing factor, a mitochondrial-flavoprotein homolog that translocates to the nucleus and fragments DNA in a caspase-independent fashion. In parallel, the drug triggers nucleophagy, an autophagic process directed at the cell’s own nucleus. Together, these two processes contribute decisively to the death of the trophozoite, the feeding and pathogenic stage of the amoeba. The finding reframes metronidazole’s lethality as a form of regulated cell death, opening the possibility that drugs designed to modulate these death pathways could potentiate existing therapy.

Transcriptomic studies of resistant Giardia lines add a genome-wide dimension to the resistance story. Analyses of laboratory-selected resistant parasites reveal coordinated changes in genes governing redox metabolism, oxidative stress responses, and energy metabolism. Rather than a single resistance mutation, resistance in Giardia emerges as a systems-level remodeling of cellular physiology: the parasite recalibrates its electron-handling networks to minimize activation of the prodrug, simultaneously bolstering its defenses against the reactive oxygen species that the activated drug generates, and adjusting its energy metabolism to accommodate the loss of pathways it has downregulated. This polygenic architecture helps explain why resistance in the clinic can be variable, difficult to predict, and dependent on the history of drug exposure in a given parasite population.

In Helicobacter pylori, the bacterium responsible for peptic ulcers and gastric cancer, the resistance landscape looks somewhat different. Here, resistance most frequently arises through mutations in, or complete inactivation of, nitroreductase-encoding genes such as rdxA and frxA. Because these enzymes are required to convert metronidazole into its active form, their loss renders the bacterium effectively blind to the drug. Additional mechanisms, including heightened oxidative stress tolerance and cellular efflux systems that pump the compound back out of the cell, can further reduce susceptibility. The contrast between the parasitic and bacterial strategies underscores a common evolutionary theme: pathogens defeat metronidazole either by refusing to activate it or by surviving and expelling its effects once activated, and both routes are being traversed in parallel across the microbial world.

The review frames these diverse findings as evidence of a continuous co-evolutionary contest between metronidazole and the pathogens it targets, a contest in which each side exploits or subverts the other’s biochemistry. The authors argue that decoding these molecular mechanisms is essential for three practical objectives: improving current therapeutic strategies, identifying new drug targets exposed by the activation and death pathways, and designing next-generation nitroimidazole derivatives or combination therapies that circumvent resistance. If activation by the malic enzyme or the NTRs can be pharmacologically enhanced, or if the apoptosis-inducing factor and nucleophagy response can be therapeutically amplified, existing doses might regain potency against resistant strains. Conversely, screening for NIM activity or rdxA mutations could guide precision prescribing. What remains clear is that metronidazole’s future depends on the continued dissection of the very anaerobic biochemistry that made it a miracle drug in the first place, and that this newly consolidated mechanistic framework offers researchers a detailed map for the battles ahead.

Subject of Research: Mechanisms of metronidazole activation, cytotoxicity, and resistance in anaerobic and microaerophilic pathogens

Article Title: Mechanistic insights into metronidazole activation and antiprotozoal action in anaerobic parasites

Article References: Bandyopadhyay, A., & Ghosh, S. K. (2026). Mechanistic insights into metronidazole activation and antiprotozoal action in anaerobic parasites. Frontiers in Parasitology, 5, Article 1946584. https://doi.org/10.3389/fpara.2026.1946584

Image Credits: AI Generated

DOI: 10.3389/fpara.2026.1946584

Keywords: metronidazole, nitroimidazole, Entamoeba histolytica, Giardia lamblia, Trichomonas vaginalis, Helicobacter pylori, PFOR, ferredoxin, nitroreductase, apoptosis-inducing factor, drug resistance, anaerobic parasites

Microproteins, often abbreviated MPs, are proteins encoded by small open reading frames, or sORFs, that typically produce peptides shorter than 100 amino acids. For decades these tiny coding sequences were dismissed as genomic noise, too short to be considered real genes and too small to yield easily detectable protein products. That view has changed dramatically over the past several years, as researchers working on humans, plants and model organisms discovered that microproteins act as regulators of processes ranging from muscle development to stress responses. Well-known examples include the LITTLE ZIPPER proteins, abbreviated ZPR, which modulate plant transcription factor networks. Yet in protozoan parasites, the functional roles and evolutionary conservation of microproteins have remained poorly understood, a gap the Taiwanese team set out to close for one of medicine’s most persistent pathogens.

Trichomonas vaginalis is a particularly compelling subject for this kind of survey. The parasite infects an estimated hundreds of millions of people worldwide, causes trichomoniasis, and is associated with increased risks of adverse pregnancy outcomes and heightened susceptibility to HIV infection. Its genome is famously large and repetitive, which complicates standard annotation pipelines and makes it a plausible refuge for uncharted small genes. Because microproteins are short and often weakly expressed, standard omics approaches struggle to distinguish genuine microprotein-coding genes from random stretches of sequence. The researchers therefore designed a multi-layered validation strategy specifically intended to overcome the limitations of conventional methods, layering independent lines of evidence so that each candidate microprotein had to survive several rounds of scrutiny.

The foundation of the analysis was transcriptomic. The team integrated bulk RNA sequencing data from 22 isolates of Trichomonas vaginalis, allowing them to ask which small open reading frames were consistently transcribed across genetically distinct parasite strains rather than appearing in only one background. This cross-isolate approach delineated what the authors describe as a stable core microproteome of 918 microprotein candidates expressed consistently across the isolates. Within that set, 786 genes correspond to core-expressed microprotein genes, while 132 candidates derive from non-annotated small open reading frames located in regions of the reference genome that had never been assigned a gene. The consistent length distribution of the expressed microproteins across all 22 isolates, ranging from very short peptides up to the 100 amino acid cutoff, underscores how stable the composition of this expressed microproteome is across the species.

One of the most striking findings concerns evolutionary novelty. When the team evaluated sequence homology between the parasite’s microproteins and the human proteome using stringent BLASTp criteria, they found that approximately 93 percent of the 918 candidates lack significant similarity to any human protein. That figure matters for two reasons. Scientifically, it suggests that the majority of these microproteins are either lineage-specific innovations or have diverged so far from their metazoan counterparts that sequence-based detection fails, making them a rich hunting ground for novel biology. Translationally, the scarcity of human homologs raises the possibility that many of these molecules could be targeted therapeutically with a reduced risk of cross-reacting with the human host, an important consideration for any future drug or vaccine development program built on this resource.

Functional predictions add further texture to the picture. About 14 percent of the identified microproteins were predicted to be membrane-associated or secreted proteins, a category of particular interest because membrane and secreted molecules sit at the interface between the parasite and its host and are prime candidates for involvement in host-parasite interactions, immune evasion and adhesion. Functional enrichment analysis of the broader set indicated that the microproteins are primarily associated with intracellular anatomical structures, ribosomal components and organelles, hinting at roles in fundamental cellular processes rather than peripheral functions. InterProScan annotation of the full candidate set, provided in the study’s supplementary tables, catalogs the domains, gene ontology annotations and pathway assignments that will let other researchers prioritize candidates for experimental follow-up.

Transcription alone does not prove translation, so the team turned to liquid chromatography coupled with tandem mass spectrometry, LC-MS/MS, to confirm that microproteins are actually made. Working with protein extracts from the isolates ATCC 30236 and PRA98, separated by SDS-PAGE and processed through both in-gel and in-solution digestion workflows, the researchers confirmed the translation of 103 microproteins. Each of these detections rests on peptide spectrum matches linking observed mass spectra to predicted microprotein sequences, providing direct physical evidence that the genome’s small open reading frames are not merely transcribed but actively translated into stable protein products. The validation results, including the breakdown of in-gel and in-solution identifications, are published as supplementary data accompanying the paper.

The third pillar of the validation strategy was single-cell RNA sequencing, employed to assess how robustly microprotein transcripts are expressed at the level of individual cells. Bulk RNA sequencing can mask heterogeneity within a population, so a transcript that appears abundant on average might in fact be produced by only a small subset of cells. The scRNA-seq analysis of isolate ATCC 30236 demonstrated that 149 of the microprotein candidates are detected in more than 50 percent of individual cells, indicating that their expression is a widespread property of the parasite population rather than a niche feature of a few cells. Single-cell prevalence data for the full candidate set are provided in the study’s supplementary tables, giving future investigators a quantitative measure of expression robustness to weigh alongside transcript abundance measured in transcripts per million.

The study’s authors emphasize that this work provides the first comprehensive atlas of microproteins in Trichomonas vaginalis and establishes a valuable resource for future functional investigations. That framing is worth taking seriously, because an atlas of this kind changes the economics of follow-up research. Instead of each laboratory having to rediscover which small open reading frames are real, expressed and translated, investigators can now start from a curated list of 918 candidates, of which 103 have mass spectrometry evidence and 149 have single-cell expression support, and select targets based on predicted localization, homology status and expression pattern. The supplementary tables, which include genomic locations, molecular weights, isoelectric points, start codons and nucleotide sequences, are designed to make that triage straightforward.

Looking ahead, the open questions are considerable. What do these microproteins actually do inside the parasite’s cells? Are the membrane-associated and secreted members of the set involved in the host-parasite interplay that determines infection severity? Do the 132 candidates from previously unannotated intergenic regions represent a class of genes that standard pipelines have systematically missed, not just in this parasite but in related protists? The Taiwanese team, supported by grants from the National Science and Technology Council and Chang Gung Memorial Hospital, has provided the map; the territory now awaits exploration. For a pathogen that has long been managed with a narrow arsenal of therapies and continues to pose public health challenges worldwide, the discovery that nearly a thousand tiny, mostly human-dissimilar proteins are woven into its biology is an invitation to look again at what a parasite genome really contains.

Subject of Research: Proteogenomic identification of microproteins encoded by small open reading frames in the protozoan parasite Trichomonas vaginalis

Article Title: A comprehensive proteogenomic landscape of microproteins in Trichomonas vaginalis

Article References: Syu, J.-W., Luo, H.-W., Lin, R., Huang, P.-J., Lee, C.-C., Yeh, Y.-M., Chiu, C.-H., Ong, S.-C., & Tang, P. (2026). A comprehensive proteogenomic landscape of microproteins in Trichomonas vaginalis. Parasites & Vectors. https://doi.org/10.1186/s13071-026-07669-7

Image Credits: AI Generated

DOI: 10.1186/s13071-026-07669-7

Keywords: Trichomonas vaginalis, microproteins, small open reading frames, proteogenomics, LC-MS/MS, single-cell RNA sequencing, transcriptomics, parasite biology, host-parasite interactions, genome annotation, sexually transmitted infection, Parasites & Vectors